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1 Zusammenfassung/Summary 
1.1 Zusammenfassung 
Morbus Basedow (Graves‘ Disease) ist eine Schilddrüsenerkrankung, die durch Auto-
antikörper verursacht wird, die hauptsächlich gegen den Thyreotropin-stimulierenden 
Hormonrezeptor (TSHR) gerichtet sind und eine Hyperthyreose zur Folge haben. En-
dokrine Orbitopathie (Graves' Orbitopathie, GO) ist eine extrathyroidale Manifestation, 
die üblicherweise im Zusammenhang mit Morbus Basedow auftritt und durch Entzün-
dung und Ausdehnung des retrookularen Bindegewebes und der extraokulären Mus-
keln (EOM) gekennzeichnet ist. Die Ausdehnung des orbitalen Gewebes in die räum-
lich begrenzte, knöcherne Orbita führt zu Proptosis, Muskeldysfunktion und in schwe-
ren Fällen zu einer Kompression des Sehnervs. Die Entzündung und Ausdehnung des 
orbitalen Gewebes kann eine Sauerstoffunterversorgung (Hypoxie) des Gewebes ver-
ursachen und somit zu einer Induktion von Hypoxie-induzierbarer Faktor 1 (HIF-1) ab-
hängigen Signalwege führen. Die vorliegende Arbeit beschäftigt sich mit der Rolle or-
bitaler Fibroblasten (OF) und/oder mesenchymaler Stammzellen (MSC) in der Patho-
genese von GO Patienten und im GO Mausmodell. Ziel war die Charakterisierung hu-
maner und muriner OF und/oder MSC im Hinblick auf Hypoxie-abhängige und unab-
hängige pathophysiologische Prozesse der GO. 
Orbitale Fibroblasten sind der zentrale Zelltyp im pathophysiologischen Prozess, und 
wurden entweder aus Fettbiopsien von GO Patienten/Kontrollpersonen oder aus orbi-
talem Gewebe eines GO Mausmodells/Kontrollmäuse gewonnen. Darüber hinaus 
identifizierten wir MSC im orbitalen Fettgewebe von GO Patienten und zeigten, dass 
OF alle biologischen Merkmale der MSC teilten: Sowohl OF als auch MSC exprimier-
ten typische MSC Oberflächen-Marker, unterdrückten die T-Zellproliferation und se-
zernierten Zytokine. Des Weiteren produzierten sie Hyaluronsäure und waren in der 
Lage sowohl adipogen, osteogen und chondrogen als auch myogen und neuronal zu 
differenzieren. Dies zeigte, dass die OF Population undifferenzierte Vorläuferzellen be-
inhaltet, die für die gesteigerte Adipogenese und/oder  Myogenese im Gewebe von 
GO Patienten verantwortlich sein könnten. 
Um zu untersuchen, ob Hypoxie-abhängige Signalwege in den Gewebeumbau bei GO 
involviert sind, analysierten wir die Rolle von HIF-1 für die Angiogenese und Adipoge-
nese unter hypoxischen Bedingungen. Als eine mögliche Folge der Hypoxiewirkung 
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fanden wir eine erhöhte Vaskularisierung und HIF-1α-positive Zellen im Binde-/Fettge-
webe von GO Patienten. Die aus dem Fettgewebe der Patienten gezüchteten OF zeig-
ten eine höhere HIF-1 Expression und sezernierten HIF-1 abhängig mehr VEGF. Des 
Weiteren wurde unter Hypoxie die adipogene Differenzierung der OF HIF-1 abhängig 
induziert. Die durch Hypoxie induzierte Adipogenese konnte durch Stimulation des 
TSHR unter Verwendung von TSH noch weiter gesteigert werden, was das ungünstige 
Zusammenwirken von Hypoxie und Effekten der Autoimmunität widerspiegelt. Rau-
chen ist der stärkste Risikofaktor für den Schweregrad einer GO und entfaltet seine 
Wirkung wahrscheinlich durch die Kombination von Rauchbestandteilen und Hypoxie. 
Interessanterweise konnten wir feststellen, dass OF von GO Rauchern im Vergleich 
zu GO Nichtrauchern höhere HIF-1α Mengen in Reaktion auf Zigarettenrauchextrakt 
und Hypoxie aufwiesen. Die erhöhte HIF-1α Expression bei GO Rauchern könnte die 
starke Gewebsexpansion, welche bei GO Rauchern beobachtet wird, begünstigen. 
Um die pathologischen Veränderungen der OF im Verlauf einer GO untersuchen zu 
können, etablierten wir ein präklinisches GO Mausmodell, das durch genetische Im-
munisierung mit einem Plasmid, welches für die humane TSHR A-Untereinheit ko-
dierte,  induziert werden konnte. Die TSHR immunisierten Mäuse entwickelten alle An-
zeichen von Morbus Basedow mit GO: Die Mäuse entwickelten TSHR-Antikörper mit 
unterschiedlichen Mengen an stimulierenden- und/oder blockierenden Antikörpern, 
eine TSHR-Antigen-spezifische Antwort von T-Zellen der Milz, Schilddrüsenfunktions-
störungen und Orbitopathie. Dabei entwickelten die Mäuse ähnlich wie GO Patienten 
im unterschiedlichen Maße eine Vergrößerung des orbitalen Fettgewebes und/oder 
eine Myopathie der EOM. Aus dem orbitalen Gewebe der Mäuse, welches überwie-
gend aus EOM und Fett bestand, isolierten und charakterisierten wir Fibroblasten. 
Ähnlich wie die OF von Patienten, exprimierten die Maus OF (mOF) typische MSC 
Marker, TSHR und Insulin Wachstumsfaktor-1-Rezeptor (IGF-1R). Ebenso zeigten 
mOF eine gesteigerte Adipogenese und vermehrte Hyaluronsäure Sekretion in Antwort 
auf TSHR und IGF-1R Aktivierung. Darüber hinaus, zeigten OF von GO Mäusen er-
höhte HIF-1α Mengen unter hypoxischen Bedingungen, was darauf hindeutete, dass 
Hypoxie-abhängige Signalwege an der Pathogenese einer GO bei Mäusen beteiligt 
sein könnten. Somit zeigten die OF von GO Mäusen einen pathogenen Zelltyp, der 
den OF von GO Patienten ähnlich ist. 
Zusammengefasst konnte gezeigt werden, dass OF und/oder MSC eine zentrale Zell-
population in der Pathogenese von GO Patienten und GO Mausmodell darstellen. HIF-
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1 abhängige Signalwege sind am Gewebeumbau und -expansion beteiligt. Das Ver-
ständnis, wie verschiedene orbitale Zellpopulationen am Gewebeumbau als Reaktion 
auf Hypoxie mitwirken, wird während des Verlaufs der Augenerkrankung im GO Maus-
modell noch weiter untersucht. Darüber hinaus ist es von Interesse die Rolle von Hy-
poxie-abhängigen Signalwege im Entzündungsprozess im Kontext der Autoimmunität 
aufzuklären. Dies kann zu einem besseren Einblick in die Pathogenese der GO führen 
und ist von grundlegender Bedeutung für die Entwicklung neuer therapeutischer An-
sätze. 
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1.2 Summary 
Graves’ disease (GD) is an autoimmune disease caused by autoantibodies directed 
mainly against the thyrotropin stimulating hormone receptor (TSHR) leading to hyper-
thyroidism. Graves’ orbitopathy (GO) is the common extra-thyroidal manifestation of 
Graves’ disease is characterized by inflammation and expansion of the retroocular 
connective/fat tissue and of the extraocular muscles (EOM). The expansion of the or-
bital tissue within the limited space of the bony orbit leads to proptosis, extraocular 
muscle dysfunction, and, in severe cases, to an optic nerve compression. Inflammation 
and enlargement of the orbital tissue can cause hypoxia and consequently induce hy-
poxia-inducible-factor 1 (HIF-1) pathways. The work presented in this thesis addressed 
the role of orbital fibroblast (OF) and/or mesenchymal stem cells (MSC) for pathogen-
esis of GO in patients and mouse model. We aimed to characterize human and mouse 
OF and/or MSC and involvement of hypoxia depending and independent pathways in 
the pathophysiological process leading to GO. 
The central cell type in this pathophysiologic process are the orbital fibroblasts (OF) 
which we derived either from fat biopsies of GO patients/control persons or from orbital 
tissue of GO/control mouse model. Additionally, we identified MSC in the fat tissue of 
GO patients and showed that OF shared all biological characteristics of MSC: Both the 
OF and the MSC expressed a typical MSC surface marker set, suppressed T cell pro-
liferation and secreted cytokines. Furthermore, the cells produced hyaluronan and 
were able to differentiate along adipogenic, osteogenic, chondrogenic, myogenic, and 
neuronal pathways. It appears that OF population comprises undifferentiated progeni-
tor cells responsible for adipogensis and/or myogenesis in GO. 
To analyze whether hypoxia dependent pathways are involved in tissue remodeling of 
GO we investigated the role of HIF-1 action for angiogenesis and adipogensis. Most 
likely as a consequence of hypoxia we found increased vascularization and HIF-1α 
positive cells in the connective/fat tissue of GO patients. OF derived thereof expressed 
higher HIF-1α levels and secreted elevated levels of VEGF in an HIF-1 dependent 
manner. Furthermore, hypoxia induced HIF-1 dependent adipogenic differentiation of 
OF which could be further increased by stimulation of TSHR using TSH indicating an 
unfavorable marriage between hypoxia and effects of autoimmunity. Smoking is the 
strongest risk factor for GO and develops it full effect most likely through smoke ingre-
dients and hypoxia. Interestingly, we found that OF derived from GO smoker more 
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strongly induced HIF-1α levels in response to cigarette smoke extract and hypoxia 
compared to GO non-smoker. Increased HIF-1α expression can contribute to the 
strong tissue expansion observed GO smoker. 
To investigate pathological changes in OF during the course of GO we established a 
preclinical mouse model of GO induced by genetic immunization of human TSHR A- 
subunit plasmid. The pathological features of GO in the experimental mouse model 
were similar in orbital pathology to those present in patients with GO; GO mice devel-
oped TSHR antibodies with different levels of stimulating and blocking activity as well 
as TSHR antigen specific response of splenic T cells. Furthermore GO mice just like 
GO patients developed thyroid dysfunction and orbital disease with mice showing ei-
ther more enlargement of orbital adipose tissue or myopathy of EOM. We derived OF 
from tissue comprise of EOM and adipose of the immunized mice. Mouse OF (mOF) 
expressed MSC marker, elevated levels of TSHR and insulin-like growth factor 1 re-
ceptor (IGF-1R) similar to OF derived from GO patients. Likewise, mOF showed in-
creased adipogenesis and enhanced hyaluronan secretion by activation of TSHR and 
IGF-1R. Moreover, in response to hypoxia OF derived from GO mice enhanced HIF-
1α levels, suggesting that hypoxia dependent signaling is involved in orbital pathogen-
esis. Thus, OF derived from GO mice display a pathogenic cell type similar to OF de-
rived from GO patients. 
In conclusion, OF and MSC are central for GO pathogenesis in patients and mouse 
model. HIF-1 dependent pathways are involved in tissue remodeling and expansion 
during pathogenesis of GO. The understanding of the contribution of different orbital 
cell populations for tissue remodeling in response to hypoxia during the course of the 
eye disease will be further studied in the GO mouse model. In addition the role of hy-
poxia for inflammation in context of autoimmunity remains to be discovered. This will 
lead to a better insight of disease pathogenesis and is fundamental to develop potential 
novel therapeutic targets. 
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2 Introduction 
2.1 Graves’ disease 
Graves’ disease (GD) is an autoimmune disorder and the most common cause of in-
sistent hyperthyroidism of the thyroid gland (Burch and Cooper, 2015). In 1840 Karl 
Adolph von Basedow reported a constellation of symptoms of goiter, exophthalmos 
and tachycardia, called the “Mersenburger Trias”. In the same century Robert James 
Graves described a case of goiter with exophthalmos. Nowadays it is known as 
“Graves’ disease” (“Morbus Basedow” in German speaking countries). Around 0.5-1% 
of the western population develops Graves’ disease during their lifetime. Graves’ dis-
ease is the most common cause of hyperthyroidism with an incidence of 20 to 
30/100.000 cases each year. Women are with 3% more frequently affected than men 
with 0.5%. The disease typically occurs between 30 and 60 years of age, but all ages 
are concerned (Wiersinga and Bartalena, 2002; Burch and Cooper, 2015). 
2.1.1 Clinical manifestations of Graves’ disease 
The disorder GD is caused by autoantibodies directed mainly against the thyrotropin 
stimulating hormone receptor (TSHR), which leads to stimulation of the thyroid gland. 
This leads to an increase in thyroid hormone levels and goiter of the thyroid gland 
(Ginsberg, 2003). The characteristic goiter is often accompanied with an infiltration of 
lymphocytes, which are the major source of autoantibodies (Weetman, 2000). Tremor, 
nervousness, emotional instability, insomnia and weight loss are typical signs of hy-
perthyroidism and chiefly traceable to the increased thyroid hormone levels (Weetman, 
2000; Burch and Cooper, 2015). Approximately, 25% to 50% of GD patients also de-
velop the extra-thyroidal manifestation Graves’ orbitopathy (GO), also called Graves’ 
ophthalmopathy. In addition, some patients develop rarely localized dermopathy and 
acropachy (Bahn, 2010; Wang and Smith, 2014). Over the last decades the number of 
patients with GD rose and reasons for this are changes in lifestyle and diet patterns. 
Also genetic and environmental factors as well as risk factors like smoking and diabe-
tes can encourage the development of thyroidal and associated manifestations of the 
disease. A variety of genes encoding proteins with immune regulatory functions are 
associated with thyroid autoimmune diseases (e.g. HLA II, CTLA-4, PTPN22, CD40). 
Furthermore, thyroid specific proteins like TSHR and Thyroglobulin are also involved 
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in the pathogenic processes of GD and associated disorders (Eckstein et al., 2009; 
McLeod and Cooper, 2012; Rosenblum et al., 2015). 
2.2 Characteristics of Graves’ orbitopathy 
Graves’ orbitopathy (GO) is the common extra-thyroidal manifestation of Graves’ dis-
ease and describes an eye disease of the orbital tissue that is characterized by inflam-
mation as well as expansion of the retroocular connective fat tissue and fibrotic extra-
ocular muscles. The expansion of the orbital tissue within the limited space of the bony 
orbit leads to proptosis, extraocular muscle dysfunction, and, in severe cases, to an 
optic nerve compression (Eckstein et al., 2009; Eckstein et al., 2016). GO patients 
show strong clinical variability of symptoms (Fig. 1).  
 
Figure 1. Patients with GO in different manifestations. Inflammation with swelling and red-
ness (A), expansion of the retroorbital fat/connective tissue with extensive proptosis (B), en-
largement of extraocular muscle volume with asymmetrical strabismus of the left eye (C), and 
impaired episcleral venous outflow with highly reddened eyes (D). Pictures show the manifes-
tation in computer tomography and the outer appearance. Images were provided by Prof. Dr. 
med. Eckstein, University Eye Hospital Essen. 
Most of the patients exhibit a combination of adipose tissue and orbital muscle expan-
sion, but some patients appear to have a predominance for one of these processes or 
only symptoms for one eye. Children develop very rarely GO and inflammation symp-
toms and myopathy are almost always missing. Patients younger than 40 years create 
mostly a predominance for adipose tissue enlargement connected with inflammation. 
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Older patients develop more frequently a myopathy of the extraocular muscles (Fig. 
1C) (Garrity and Bahn, 2006; Eckstein et al., 2009; Bahn, 2010; Eckstein et al., 2016). 
Around 25-50% of GD patients develop GO in varying degrees (Fig. 2). For most of the 
patients a mild form occurs and can be treated with symptomatic treatment, but in 
around 3-5% of the cases the clinical course is severe and often orbital decompression 
surgery is necessary. It is largely unclear why some patients with GD develop a GO, 
unlike other patients show no symptoms or to a lesser extent (Eckstein et al., 2009; 
Wang and Smith, 2014; Banga et al., 2015). This is reflected in more or less active 
inflammation, fat and muscle expansion and fibrosis in the different patients. The clin-
ical manifestation can also vary widely due to environmental influences and genetic 
background (Tomer and Davies, 2003). The strongest GO associated risk factor is cig-
arette smoking, which leads to higher prevalence of GO, a more severe course of the 
disease and a reduced response to anti-inflammatory treatment (Pfeilschifter and Zieg-
ler, 1996; Eckstein et al., 2004; Cawood et al., 2006) . Further, the levels of stimulating 
TSHR antibodies affect the severity of GO (Eckstein et al., 2006). 
Figure 2. Rundle curve of activity and severity of GO. The graphs showing the activity (red 
line) and severity (blue line) of orbital manifestation in severe and mild course of GO patients 
as well as treatment and surgery methods. Adapted from Cawood et al., 2004. 
The amount of activity is scored by the clinical activity score (CAS). This score is based 
on classical signs of inflammation (pain, swelling, and impaired function) and use a 
points system ranged from 0-10. In contrast the NOSPECS („no signs or symp-
toms“/„only signs or symptoms“/„soft tissue involvement”/ Proptosis/„extraocular mus-
cle involvement“/„corneal involvement“/„sight loss“; EUGOGO) classifies severity ac-
cording to occurrence and amount of lid retraction, lid lag, proptosis, restrictive extra-
ocular myopathy and optic neuropathy (Mourits et al., 1997; Bartalena et al., 2016). 
Both scores are used for a standardized assessment and are required for treatment 
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decisions of the disease. The disease starts with an initial phase, called the active 
phase, which is characterized by inflammatory mediators and immigrant immunocom-
petent cells. This leads to fibrosis/myopathy of the affected regions and to a fat prolif-
eration, which can caused the protrusion of the eyes. The following phase is the chronic 
inactive phase in which patients suffer from the permeant persistence of myopathy and 
proptosis (Eckstein et al., 2009; Bahn, 2010). 
2.2.1 Stage dependent treatment of Graves’ orbitopathy 
The clinical presentation of Graves’ orbitopathy is closely linked with the formation of 
hyperthyroidism and usually develops within 6 months together with thyroid dysfunc-
tion. For a successful therapy an early diagnosis is important, because immunosup-
pressive and modifying therapies are much better effective when GO is in a recent 
active stadium. Prerequisite for an effective treatment of GO is the successful treat-
ment of thyroid dysfunction to restore the euthyroid status (Eckstein et al., 2007; Eck-
stein et al., 2016). Euthyriodism favors the immunosuppressive treatment of orbital 
symptoms and can be achieved primarily by thyrostatic therapy (Salvi and Campi, 
2015). In cases of medication not being effective or having a relapse, the thyroids 
should be definitive treated either by radioiodine therapy or surgical removal. The treat-
ment of GO depends on clinical activity and severity of eye disease and can be derived 
from the clinical activity score (CAS) and NOSPECS score of the GO patients (Mourits 
et al., 1997). To simplify treatment decision GO can be classified into mild, moderate 
to severe or sight-threatening disease (Fig. 3). 
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Figure 3. Therapy management of Graves’ orbitopathy. Treatment strategy is based on 
severity/activity classification grouped in mild, moderate to severe and sight-threatening dis-
ease grades. Rehabilitative surgery includes orbital decompression, squint surgery, lid length-
ening, and blepharoplasty. i.v. GCs, intravenous glucocorticoids; OR, orbital radiotherapy; 
DON, dysthyroid optic neuropathy. Diagram of therapy formulated from EUGOGO, 2008 
(Bartalena et al., 2008; Bartalena et al., 2016). 
In mild cases the general approach is a wait-and-see attitude, when patients have no 
suffering and a favorable risk profile. In situations the patient´s psychological strain 
require the treatment of mild cases selenium and/or glucocorticoids are reported to 
have positive effects (Bartalena et al., 2008; Bartalena et al., 2016). In patients with 
moderate-to-severe and sight-threatening GO an immunosuppressive therapy with 
glucocorticoid is indicated. The therapy with such drugs should lead to attenuation of 
the ongoing inflammation process. When patients are 6 month inactive and stable or 
when sight-threatening complications are present, an orbital decompression can/has 
to be performed. The aim of the bony orbital decompression is the treatment of the 
compartment syndrome within the bony orbit and the reduction of the exophthalmos 
(Bartalena et al., 2008; Salvi and Campi, 2015; Bartalena et al., 2016). Against the 
background of such serious consequence, it is to be considered that risk factors like 
smoking enhance not only the severity of the disease, but also increase the relapse 
rate. Further, the effectiveness of anti–inflammatory drugs is decreased in smokers. 
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Therefore, all patients should be actively encouraged to stop smoking (Hegedius et al., 
2004). 
 
In recent years several new treatment approaches have been found and studied. One 
is the immune modifying therapy with the CD20+ B-cell attacking Rituximab which 
shows controversial data. A study by Salvi et al. 2015, which compared Rituximab with 
steroids, a promising therapeutic effect has been proved (Salvi et al., 2015). However, 
another Rituximab study could not show the same effect, but it can be assumed that a 
different timing of the treatment lead to divergent results (Stan et al., 2015). Only the 
really treatment is successful in such a disease where early fibrosis and adipogenesis 
is trigger by inflammatory stimuli. A potential novel therapeutic approach is the com-
bined or single targeting of TSHR or IGF-1R. The TSHR can be targeted by either 
TSHR blocking antibodies like 5C9 and K1-70 (Sanders et al., 2010) or small TSHR 
blocking molecules, antagonists such as ANTAG2 and ANTAG3 (Neumann et al., 
2011). Potential antibodies for IGF-1R blocking activities are Teprotumumab and the 
small molecule Linsitinib (Neumann et al., 2015). But all of these substances are not 
yet tested on patients (accept Teprotumumab – results of a randomized controlled trial 
(RCT) are on the way) and therefore the therapy of GO patients is still heavily based 
on corticosteroids, orbital irradiation and surgical decompression. Further profound 
studies and new treatment strategies need to be developed. 
2.2.2 Pathogenesis of Graves’ orbitopathy 
The pathogenesis is very complex and multifaceted and local mechanisms for the de-
velopment of GO are not fully understood. The interaction between various cells in the 
pathophysiological process of GO can support orbital inflammation and tissue expan-
sion. In this process, immune cells like T-cells, B-cells, monocytes, macrophages and 
mast cells are involved while immigrating in the orbit. But most likely, the local orbital 
fibroblasts (OF) are the key players in the pathology of GO (Bahn, 2015; Smith and 
Hegedus, 2017). For a long time OF appeared as passive cells with more structural 
roles. Today OF are recognized as a heterogeneous cell population that fulfill complex 
functions in the normal and pathophysiological processes of tissue homeostasis. Or-
bital fibroblast were frequently derived from retro-bulbar connective/fat tissue of GO 
patients and in vitro studies thereof revealed that auto-antibodies against the TSH-
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receptor (TRAK) and IGF-1R as well as cytokines and growth factors and interaction 
with immune cells activate the orbital fibroblasts (Bahn, 2010). 
 
Role of orbital fibroblasts in Graves’ orbitopathy 
It could be shown that the interaction between autoimmunity and symptoms of GO are 
induced via TSHR, IGF-1R and CD40 activation (Fig. 4).  
 
Figure 4. Pathophysiological processes in orbital tissue of GO patients. The orbital fibro-
blasts are the key players involved in four important mechanisms of GO pathophysiology: 1. 
Inflammation, 2. Autoimmunity, 3. Differentiation in adipocytes or/and myocytes and 4. Prolif-
eration and hyaluronan production (fibrosis). These processes lead to expansion of the orbital 
connective/fat tissue and EOM as well as to continuous inflammation. 
The orbital fibroblasts expressed TSHR, IGF-1R and CD40 more abundantly in GO 
patients than in controls (Bahn et al., 1998; Valyasevi et al., 1999; Kumar et al., 2004; 
Hwang et al., 2009; Bahn, 2010; Wang and Smith, 2014). The activation of these re-
ceptors elicits signaling cascades stimulating the production of glycosaminoglycan like 
hyaluronan, enhanced adipogenic differentiation, and leads to secretion of cytokines 
as well as inflammatory mediators (Bahn et al., 1987; Heufelder and Bahn, 1994; Bahn 
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et al., 1998; Iyer and Bahn, 2012). Interaction of T cells with OF via CD40-CD154 liga-
tion enhances the proliferation and expression of cytokines in OF (Feldon et al., 2005; 
Hwang et al., 2009). Heterogeneity of OF population in the orbital tissue derived from 
GO patients can lead to different adipogenic or myogenic differentiation ability and se-
cretion of inflammatory mediators. One reason might be based on surface expression 
of the glycoprotein CD90 (Thy1). CD90 is a glycophospharidylinositol (GPI)-anchored 
surface protein which plays immunological roles in T cell activation (Rege and Hagood, 
2006) and non-immunological roles in cell-cell and cell-matrix interactions, apoptotic 
signaling, metastasis, inflammation and fibrosis (Khoo et al., 2008). CD90 negative OF 
are reported to differentiate to adipocytes and to produce higher levels of cytokines, 
such as IL-6. However, CD90 positive OF appeared to differentiate into myocytes in 
response to TGF-β stimulation (Koumas et al., 2002; Douglas et al., 2010; Smith, 
2010). These findings suggest that CD90 negative cells are involved in orbital inflam-
mation and adipogenesis whereas CD90 positive OF predominantly differentiate in my-
ocytes and most likely play a role in EOM fibrosis. Relative portion of CD90 negative 
and/or positive OF, represent in the orbital tissue might explain why some GO patients 
developed more fat expansion whereas others show more muscle involvement or in-
flammation signs (Smith et al., 2002). 
 
Inflammation and effects of autoantibodies in orbital fibroblasts 
As described before, the expression of TSHR in GO tissue is increased compared to 
control (Ctrl) tissue (Bahn, 2010). Levels of TSHR autoantibodies (TRAbs) correlate 
positively with the clinical activity score (CAS) and the prevalence of GO (Khoo et al., 
1999; Gerding et al., 2000). In sera of GO patients a mixture of stimulating (TSAbs), 
blocking (TSBAbs) and cleavage (neutral) TSHR autoantibodies, which bind on differ-
ent regions in the TSH-receptor are found (Fig. 5) (Evans et al., 2010). While TSAbs 
mimic the actions of TSH and initiate the TSHR signaling cascade leading to hyperthy-
roidism, TSBAbs inhibit TSHR stimulation by TSH leading to a decrease of thyroid 
hormone secretion (Rees Smith et al., 1988; Jaume et al., 1997). Several assay exist 
to quantify TRAbs and TSAbs in sera of patients  (Costagliola et al., 1999; Schott et 
al., 2009; Allelein et al., 2016). However, TBAbs can only be detected indirectly in a 
bioassay by measuring decreased production of cAMP in a cellular system (Diana et 
al., 2015). Stimulating antibodies partially bind to the leucine rich repeats (LRRs) and 
induce a structural change of the receptor which leads to signal transduction. However, 
blocking antibodies also bind to the LRRs but this binding cannot change the structure 
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of the receptor for signal transduction. Cleavage antibodies bind to the cleaved region 
and/or the N terminus of the TSHR ectodomain and this neither induce signal trans-
duction nor block TSH binding (Davies et al., 2005). TSH or TSHR stimulating antibod-
ies lead to an activation of the TSHR on the OF and induce the expression of cytokines 
and growth factors like ICAM1, HLA-DR, IL-6 and increased hyaluronan production 
(Kumar et al., 2011). Additionally the phosphatidyl inositol 3 (PI3) kinase pathway is 
involved which play a role for adipogenic differentiation of OF (Zhang et al., 2009; van 
Zeijl et al., 2011).  
 
Figure 5. TSHR and IGF-1R as targets for autoantibodies. (A) Structure of G protein-cou-
pled TSHR and (B) structure of tyrosine kinase IGF-1R. (C) A hypothetical model to explain 
the effect of structural changes in the TSH-binding site of the TSHR by stimulating, blocking or 
cleavage TSHR antibodies (Davies et al., 2005; Kavran et al., 2014). Binding of stimulatory 
(TSAbs), blocking (TSBAbs) or cleavage antibodies to the TSHR leads to different signal path-
ways and functional consequences, like stimulation, inactivation or cell death of thyrocytes. 
(Morshed and Davies, 2015). For example, TSAbs elevated hyaluronan production of OF that 
could be abolished by TSBAbs (Turcu et al., 2013). The action of cleavage TSHR antibodies 
in OF is currently unknown. 
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In thyrocytes TSHR blocking as well as neutral antibodies are also able to trigger signal 
pathways. TSHR blocking antibodies are involved in diverse multiple signaling cas-
cades like, cell proliferation and increase Akt, CREB, c-Raf and ERK, which are im-
portant pathways for thyroid cell survival and proliferation. TSHR cleavage antibody 
action leads to apoptosis via mitochondrial ROS induction through suppressing 
PKA/CREB/AKT pathways (Morshed et al., 2010; Morshed et al., 2013; Morshed and 
Davies, 2015). The influence of these antibodies in GO-OF and in the pathological 
mechanisms of GO remains to be examined. 
 
Furthermore, the IGF-1R is also a possible target for the autoantibodies in GO and is 
expressed at high levels on orbital fibroblasts (Khoo and Bahn, 2007). Studies found 
that sera from GD patients contained IGF-1R stimulatory antibodies that can induce 
the production of the T-cell chemoattractants IL-16, RANTES as well as hyaluronan in 
OF (Pritchard et al., 2003; Smith and Hoa, 2004). However, Minich et al. could not 
found anti-IGF-1 antibodies in sera of GO patients (Minich et al., 2013). It is also re-
ported that there is a functional interaction between the TSHR and the IGF-1R in OF. 
Krieger and co-workers discovered that the activation of both TSHR and IGF-1R by 
monoclonal TSHR stimulatory antibody M22 leads to enhanced hyaluronan production 
of OF by using the dual-signaling cascade (Krieger et al., 2015). However, in this cross-
talk model anti-IGF-1R antibodies were not implicated but instead stimulatory TSHR 
antibodies can activate TSHR and IGF-1R (Krieger et al., 2016).  Apparently, around 
30% of the TSHR mediated action happens via IGF-1R activation (Place et al., 2016). 
 
Fibrosis and orbital fibroblasts 
It could be shown that proliferation activity of OF derived from GO patients are higher 
than in control OF. The CD40-CD154 interaction between T-cells and OF but also cy-
tokines and growth factors (e.g. IL-4, IGF-1 and TGF-β) lead to further enhancement 
of the proliferation rate (Heufelder and Bahn, 1994; Feldon et al., 2005). Additionally, 
OF are able to produce hydrophilic glycosaminglycans (GAGs), especially hyaluronan 
(Smith et al., 1991; Smith et al., 1995). Hyaluronan is essential in the orbital tissue as 
a component of the extracellular matrix. Hyaluronan is a main component of the ex-
pansion of the orbital tissue in GO patients. Three hyaluronan synthases (HAS1-3) 
control hyaluronan abundance but HAS2 is considered to represent the major contrib-
utor of hyaluronan overproduction in the orbit and may cause a greater expansion of 
the fat compartment in GO (Kaback and Smith, 1999, 1999). In addition, hyaluronan 
2 Introduction     16 
 
secretion can also increase the size of muscle belly. Cytokines like IL-1β and CD40 
ligand can cause an increase of hyaluronan production but also cellular interactions 
between OF and immune cells (mast cells and lymphocytes) are involved (Smith et al., 
1991; Smith and Parikh, 1999). Tissue expansion and fibrosis are the major reason for 
myopathy and proptosis in GO and enhanced proliferation and hyaluronan overpro-
duction of OF favor this pathological process. 
 
Differentiation ability of orbital fibroblast 
Differentiation ability is dependent on the phenotypical heterogeneity of OF. Two OF 
subpopulations depending on CD90 expression, CD90 negative and CD90 positive OF 
can be derived from orbital tissue of GO patients. Orbital fibroblasts which are CD90 
negative have a high capacity to differentiate into adipocytes. The differentiation pro-
cess into adipocytes increases the expression of adiponectin, leptin, PPAR-γ as well 
as enhanced TSHR presentation and cytokine production like IL-1β, IL-6 and IL-8 (Val-
yasevi et al., 1999; Koumas et al., 2002). 
On the other hand, there is a pool of CD90 positive OF present in the orbital tissue. 
These OF are more abundant in the extra-ocular muscles and are not able to differen-
tiate in adipocytes. However, in response to TGF-β the CD90 positive OF differentiate 
to myocytes (Koumas et al., 2003). It is described that the clinical manifestation of GO 
can be divided into two subtypes, which are characterized by either predominant fat 
expansion or EOM enlargement (Hiromatsu et al., 2000). A relative portion of either 
CD90 negative or positive OF in the orbital tissue might explain why some GO patients 
developed more fat expansion whereas others show more muscle involvement or in-
flammation signs (Smith et al., 2002). Recently, Kuriyan et al. demonstrated that two 
subtypes of clinical manifestations of GO patients showing either more fat expansion 
or EOM expansion corresponded to either enhanced adipogenesis or stronger prolif-
eration rate of OF derived from the respective GO patients (Kuriyan et al., 2013). The 
interrelation of these cellular mechanisms causes an enormous increase in volume of 
the orbital tissue. Swelling and processes of inflammation in the limited bony orbit can 
encourage the long-term tissue hypoxia. 
 
Smoking as a risk factor and effects on orbital fibroblasts 
1987 Hagg and colleagues first described the association between smoking and 
Graves’ orbitopathy (GO). Smoking is the strong risk factor and harmfully affects GO 
pathogenesis. A dose-dependent relation is known between the number of cigarettes 
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and development OF GO, with current smokers having a higher risk than past smokers 
(Hegedius et al., 2004). Disease development occurs more frequently and tend to be 
more severe in smokers than in non-smokers (Hagg and Asplund, 1987; Pfeilschifter 
and Ziegler, 1996). Studies could show that smoking can stimulate the generation of 
reactive oxygen species (ROS) and enhances proliferation and adipogenesis of the 
orbital tissue (Cawood et al., 2007; Yoon et al., 2013). The molecular process of fat 
expansion in the limited space of the body orbit is induced trough the differentiation 
potential of orbital fibroblasts and preadipocytes to mature adipocytes. Investigations 
with cigarette smoke extract showed a dose-dependent enhancement of OF adipogen-
esis. A relationship between orbital adipogenesis and ROS generation during cigarette 
consumption was shown (Yoon et al., 2013). Additionally, cigarette smoke stimulates 
the proliferation of OF. Hypoxic conditions as well as ROS have an additive effect on 
the proliferation and modulation of cytokine networks of OF (Cawood et al., 2007; Eck-
stein et al., 2009). The effect of smoking can be due to a combination of hypoxia, ROS 
and smoke ingredients. 
2.3 Role of hypoxia 
Energy generation of somatic cells is covered by the combustion of oxygen. Accord-
ingly acute hypoxia leads to cell damage and can be trigger various serious diseases 
(Ziello et al., 2007). Oxygen concentration varies significantly in different tissues and 
range from 2.5% to 14% in highly perfused organs such as lung, kidney and heart. 
However, adipose tissue has low oxygen levels of 3% or less (Trayhurn, 2013). Hy-
poxia is a main factor in the pathophysiology of heart attack, stroke, when tissue ex-
pands by cancer or obese, in inflamed tissue and in many other disorders (Park et al., 
2004). Further, it is possible that hypoxia is induced by smoking. The cells respond to 
the hypoxic microenvironment by adapting gene expression through the activation of 
Hypoxia-inducible factor 1 (HIF-1) (Semenza, 1998). 
2.3.1 Transcriptional activator Hypoxia-inducible factor 1 
Hypoxia-inducible factor 1 (HIF-1) is a transcription factor which controls the expres-
sion of most genes involved in adaption to hypoxic conditions (Semenza, 1998). HIF-
1 is a heterodimeric transcription factor, composed of a α- and β-subunit (Fig. 6). Anal-
ysis found two HIF-1α homologues called HIF-2α and HIF-3α with structural similarity 
and interaction with HIF-1β. HIF-3α is the less related isoform and the regulation and 
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its transcriptional role under hypoxia is unclear (Carroll and Ashcroft, 2006). HIF-2α is 
closely related and binds to the same cDNA sequence as HIF-1. Both have similar 
post-translation, oxygen-sensitive modes of regulation but their expression patterns 
appears to be tissue specific (Ratcliffe, 2007). In contrast to HIF-1α which is ubiqui-
tously expressed whereas HIF-2α is predominantly expressed in the lung, endothelium 
and carotid body (Ke and Costa, 2006). Studies in HIF-1α or HIF-2α knock-out mice 
demonstrate non redundant roles of HIF-1α and HIF-2α and result in different pheno-
types of these mice (Ratcliffe, 2007; Lisy and Peet, 2008). 
 
Figure 6. Schematic representation of α- and β- subunits of the transcription factor HIF. 
HIF is a heterodimeric transcription factor composed of an α-subunit and a ß-subunit. Three 
homologue α-subunits exist. The subunits have at its N-terminal end a helix-loop-helix (bHLH), 
as well as a Period/ARNT/single minded (PAS) domain. The function of bHLH is DNA binding, 
whereas the PAS domain mediated the dimerization between the both subunits. The α-subu-
nits have an oxygen-dependent degradation domain (ODDD) with two hydroxylation sites (HIF-
1α: Pro402; Pro564, HIF-2/3α: Pro405; Pro530) and a C-terminal transactivation domain (C-
TAD), expect HIF-3α, with one further hydroxylation site (Asn803). The total number of amino 
acids of each subunit is marked at the end of the domain (Ke and Costa, 2006; Weidemann 
and Johnson, 2008; Lisy and Peet, 2008). 
The 120 kDa α-subunit is strictly oxygen dependent, while the small β-subunit (94 kDa) 
is constitutively expressed (Stolze et al., 2002). Structures of both subunits show many 
homologies, which play a central role in the adaptation to hypoxia and for the regulation 
of HIF specific target genes. Both subunits possess a helix-loop-helix- (bHLH) on the 
amino terminal end as well as a PER-ARNT-SIM (PAS)-Domain. The bHLH domain 
mediates the DNA binding and the PAS domain’s function is to dimerize between the 
both subunits. In contrast to HIF-1β, HIF-1/2α isoforms have additional functional pro-
tein domains (Weidemann and Johnson, 2008; Lisy and Peet, 2008; Berchner-
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Pfannschmidt et al., 2010). These include the oxygen-dependent degradation domain 
(ODDD) as well as an N-terminal and C-terminal transactivation domain (N-TAD, C-
TAD). The role of these transactivation domains is the interaction with cofactors, which 
are decisive for the complete activity of HIF. The oxygen-dependent hydroxylation of 
the ODDD domain serve the interaction with the von Hippel-Lindau tumor suppressor 
protein (pVHL) (Weidemann and Johnson, 2008; Berchner-Pfannschmidt et al., 2010). 
2.3.2 Regulation of Hypoxia-inducible factor 1 
HIF-1 is subject to a number of regulatory post-translational modifications, wherein the 
modification of the α-subunit is of particular interest (Fig. 7). 
 
Figure 7. Oxygen dependent regulation of HIF-1α through post translational hydroxyla-
tion. Under high oxygen levels prolyl hydroxylases (PHD) hydroxylate two prolines residues 
existing in the ODDD domain of HIF-1α while factor inhibition HIF enzyme (FIH) hydroxylate a 
proline residues in the C-TAD domain. The pVHL protein detect the hydroxylated prolyl resi-
dues in the ODDD and initiates the ubiquitination and proteasomal degradation. The hydrox-
ylated prolyl residue in the C-TAD domain prevents the interaction of HIF-1α with coactivator 
CBP/p300. Under Hypoxia, PHD and FIHs are inactive leading to stabilization of HIF-1α and 
dimerization of the HIF-1α/β transcription complex. Non-hydroxylation of the C-TAD domain 
allows CBP/p300 recruitment, resulting in activation of target gene expression (Weidemann 
and Johnson, 2008; Berchner-Pfannschmidt et al., 2010). 
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The fast degradation of HIF-1α under normoxia is mediated via hydroxylation pro-
cesses. In the presence of O2, HIF is targeted for degradation by an E3 ubiquitin ligase 
containing pVHL (Fig. 7). pVHL binds to HIF-1α when the proline residues are hydrox-
ylated by the prolyl hydroxylases (PHD1-3) in the presence of O2 under normoxia. VHL 
is part of the VCB-Cul2 E3 ligase complex that includes Elongin B, Elongin C, Cullin-
2, Rbx-1. This complex, together with an ubiquitin-activating enzyme (E1), mediates 
the ubiquitination and proteasomal degradation of HIF-1α. In addition, the cofactor re-
cruitment is prevented by asparagine hydroxylation at the C-TAD domain via factor 
inhibition HIF enzyme (FIH) under normoxia. The half-life period of HIF-1α is lesser 
than 5 minutes. In this short time period there a no possibilities to generate a functional 
transcription complex (Ke and Costa, 2006; Berchner-Pfannschmidt et al., 2007; 
Weidemann and Johnson, 2008). 
However, if a critical oxygen concentration is undershot (Hypoxia), hydroxylation of 
HIF-1α is reduced and HIF-1α can stabilize and translocate in the nucleus where HIF-
1α built a heterodimer with the constitutively expressed HIF-1β. The complete tran-
scriptional activity of HIF-1 is regulated via the co-factor complex CBP/p300. HIF-1 
activates more than 100 target genes via the hypoxia response element (HRE) (Chen 
et al., 2001; Ke and Costa, 2006; Weidemann and Johnson, 2008). 
2.3.3 Hypoxia-inducible factor 1 target gene expression 
Tissue and cells undersupplied with oxygen need to adapt to the hypoxic environment. 
The organism tries to recover the oxygen supply by various regulatory mechanisms 
which have to be activated. HIF-1 activates the expression of its target genes by bind-
ing to the hypoxia response element (HRE). Gene products of HIF-1 are involved in 
many cellular processes like erythropoiesis, glucose metabolisms, angiogenesis, cell 
proliferation, and adipogenesis (Ke and Costa, 2006) (Fig. 8). 
One of the main oxygen-regulated glycoprotein is erythropoietin (EPO) which stimu-
lates the proliferation, survival and differentiation of erythroid stem cells. Under heavy 
loss of blood or under hypoxic conditions expression of EPO can be increased up to 
1000-fold. While hypoxia increases the expression of EPO, which is necessary for the 
formation of new red blood cells, the increased blood cell number enhances the deliv-
ery of oxygen supply. With this process the body adapts to regulate inadequate oxygen 
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conditions (Grimm et al., 2002; Arjamaa and Nikinmaa, 2006). Another important pro-
cess to adapt on hypoxia is developing new blood vessels. A well-known growth factor 
for angiogenesis is the vascular endothelial growth factor (VEGF). VEGF stimulates 
the angiogenesis by recruiting endothelial cells into hypoxic and avascular areas and 
enhances their proliferation. HIF-1 induces the expression of genes involved in new 
formation and ingrowth of bold vessels in undersupplied areas (Ke and Costa, 2006; 
Arjamaa and Nikinmaa, 2006). Eukaryotic cells respond to low oxygen supply by 
switching to the oxygen-independent glucose metabolism (glycolysis). The switch from 
aerobic to anaerobic respiration is prerequisite for the adaption on hypoxic conditions. 
HIF-1 induces genes such as glycolytic enzymes and glycose transporter GLUT-1 and 
GLUT3. The enhanced expression of glycolytic enzymes and transporters allows an 
increased glycose uptake (Chen et al., 2001; Lu et al., 2002). 
 
Figure 8. Involvement of HIF-1 gene products in cellular processes. Up to 100 target 
genes of HIF-1 are known (Chen et al., 2001; Ke and Costa, 2006; Weidemann and Johnson, 
2008). Gene products of HIF-1 are involved in many cellular processes like erythropoiesis, 
glucose metabolisms, angiogenesis, cell proliferation, and adipogenesis. COLAGN, collagen, 
VEGF, vascular endothelial growth factor; GLUT-1/-3, glucose transporter 1/3; IGF2, insulin-
like growth factor 2; EPO, Erythropoietin; AdiQ, adiponectin.  
It has been reported that hypoxia is also involved in the expansion of adipose tissue 
for example in obese or cancer (Lu et al., 2002; Cawood et al., 2004). The expansion 
of adipose tissue is indicated in GO as well as enhanced levels of leptin, adiponectin, 
PPAR-γ, and CD90 (Lantz et al., 2005; Kumar et al., 2005; Khoo et al., 2008). The 
ability of orbital fibroblasts to differentiate in adipocytes leads to an increased adipo-
genesis of OF, with effects on enhanced TSHR expression and cytokine production 
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(Valyasevi et al., 1999; Kumar et al., 2005). In many pathophysiological states it has 
been reported that HIF-1 is involved as a mediator for the adaption to hypoxic condi-
tions. However, no such information is available for hypoxic influences and HIF-1 de-
pendent pathways in orbital tissue of GO patients. Therefore, it is important to investi-
gate the role of HIF-1 and HIF-1 specific target genes signaling. 
2.4 Animal models in Graves’ orbitopathy 
Animal models are indispensable for the understanding of the pathology and treatment 
options of autoimmune diseases. But at present there are none spontaneous models 
of GD including GO (Ludgate, 2000). The existing mouse models of GD depend mainly 
on genetic induction by using plasmids or adenovirus based methods (Wiesweg et al., 
2013; Banga et al., 2016). A transgenic spontaneous model of GD has been developed 
recently (Rapoport et al., 2015; Rapoport et al., 2016). Unfortunately, all of this GD 
mouse models lacked signs of GO. For the understanding of the pathophysiological 
processes in GO, particularly for the examination of early states of GO and for the 
development of new treatments, it is necessary to develop other methods to induce 
GD with GO pathology in mice (Banga et al., 2016).  
The first inducible mouse model was created in 1996 by Shimojo et al., and induced 
Graves hyperthyroidism in mice by immunization with TSHR receptor transfected fibro-
blasts. This approach leads to TSHR in vivo expression and production of TSHR anti-
bodies expressing cells (Shimojo et al., 1996). The model showed an incidence of 10-
15% with low hyperthyroidism and was reproducible with some improvements (Shimojo 
et al., 1996; Kita et al., 1999; McLachlan and Rapoport, 2004). Many other groups 
process different models with various methods. The methods include injection of TSHR 
expressing cells like the first described model, or genetic immunization via TSHR A-
subunit plasmid or TSHR encoding adenovirus. But all of these models have proven 
not to be able to induce orbital signs or orbital symptoms were not reproducible. Only 
three studies reported mouse models with orbital complications but these models were 
not reproducible (McLachlan et al., 2005; Banga et al., 2015). Thus an important hall-
mark of animal models of GD is the ability to form orbital complications like inflamma-
tion, muscle enlargement, and expansion of the orbital connective tissue as well as 
eye signs such as lid swelling, redness, and edema (Banga et al., 2016; Ungerer et al., 
2016). 
2 Introduction     23 
 
In 2013 Moshkelgosha et al. established a promising new approach of genetic immun-
ization of the human TSHR A-subunit encoding plasmid by electroporation of the leg 
muscles (Fig. 8). The human TSHR A-subunit immunized mice developed sustained 
levels of TSHR antibodies with varying degrees of stimulating and blocking antibodies 
leading to either hyperthyroidism or hypothyroidism of the mice. Moreover the immune 
mice showed orbital disease including inflammation of EOM, adipogenesis with expan-
sion of retrobulbar adipose tissue and chemosis including dilated and congested orbital 
blood vessels (Moshkelgosha et al., 2013). To further study on disease pathology and 
novel therapeutics it has been important to initiate a comparative study to evaluate the 
model in two independent locations with different housing conditions and environmen-
tal factors. 
 
Figure 9. Induction of GO in mouse model by genetic immunization. Plasmids encoding 
for the human TSHR A-subunit or for ß-Galactosidase as a control plasmid were injected and 
electroporated in the big leg muscles of female BALB/c mice four times at 3-week intervals. Six 
to 15 weeks after the last immunization mice were sacrificed and serum, thyroids and orbits 
were investigated (adapted from Moshkelgosha et al., 2013; Rapoport and McLachlan, 2016). 
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2.5 Principal issues addressed in this thesis 
Graves’ orbitopathy (GO) leads to significant limitations in quality of life of patients, 
which may be symptomatic and physical strain. The medical treatments are not yet 
matured and molecular processes of the disease are incompletely understood. The 
studies which are included in this thesis aimed for a better understanding of molecular 
mechanisms and pathophysiological processes of tissue remodeling in GO. Although 
OF are considered to play an important role in tissue remodeling and inflammation, the 
orbital cell population of GO patients has been incomplete characterized. Differentia-
tion of OF and resulting tissue expansion in conjunction with inflammation and the lim-
ited volume of the bony orbit can cause hypoxia. However the hypoxic response of OF 
has been unknown.  
At the start of the thesis the recently described GO mouse model (2013), has not been 
reproduced and mouse OF were not available to study hypoxic and other pathways 
during the course of disease. 
 
The aim of this thesis was the investigation of characteristics, immune modulation and 
differentiation ability of orbital cell populations derived from GO patients as well as GO 
mouse model. During the course of the thesis the GO mouse model should be estab-
lished and reproduced to obtain and to characterize mouse OF. Furthermore, the role 
of hypoxia as a tissue remodeling driving factor has to be exploited. The understanding 
of the regulation and activation of orbital cell populations and role of hypoxia induced 
pathways in OF could be fundamental to develop potential novel therapeutic targets. 
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Publication 1 
 
 
 
Orbital fibroblasts from Graves‘ Orbitopathy patients share 
functional and immunophenotypic properties with  
mesenchymal stem/stromal cells. 
 
Brandau S, Bruderek K, Hestermann K, Görtz G-E, Horstmann M, Mattheis S, 
Lang S, Eckstein A, Berchner-Pfannschmidt U. 
 
Invest Ophthalmol Vis Sci. 2015, 56:6549-5756 
 
 
 
 
 
 
 
 
 
 
Contribution 
Herein I performed cell culture experiments to analyze hyaluronan production like in 
Fig. 1 and neurogenic differentiation potential (Fig. 3) of OF and MSC derived from GO 
patients and control persons. I designed the experimental conditions and performed 
hyaluronan ELISA, neurogenic differentiation assay, staining of the cells and micros-
copy. I analyzed the obtained data and contributed to interpretation of the results. I was 
involved in writing methods and results of the publication. 
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Publication 2 
 
 
 
Hypoxia-dependent HIF-1 activation impacts on tissue re-
modeling in Graves’ ophthalmopathy- Implications for 
smoking. 
 
Görtz G-E, Horstmann M, Anol B, Delos Reyes B, Fandrey J, Eckstein A, Berchner-
Pfannschmidt U. 
 
J Clin Endocrinol Metab. 2016, 101(12):4834-4842 
 
 
 
 
 
 
 
Contribution 
In this study I isolated OF from orbital fat tissue of GO patients and control persons. I 
performed cell culture experiments under hypoxia and analyzed HIF-1α and HIF-1 tar-
get gene expression by using western-blot, immunofluorescence microscopy, as well 
as real time PCR and ELISA like in Fig. 1-3, 5 and 6. I was involved in immuno-histol-
ogy and microscopy of orbital biopsies and conducted quantification of CD31 staining 
(Fig. 4, supplementary Fig. 1). I established adipogenesis assay and quantified adipo-
genic differentiation of cells in response to hypoxia, TSH and HIF-1 inhibitor (Fig. 5, 
supplementary Fig. 2). I designed experiments and was centrally involved in discussing 
and analyzing data. I contributed to writing of abstract, introduction, methods, results 
and discussion of the publication. 
3 Publications  39 
 
 
3 Publications  40 
 
 
3 Publications  41 
 
  
3 Publications  42 
 
  
3 Publications  43 
 
  
3 Publications  44 
 
  
3 Publications  45 
 
  
3 Publications  46 
 
  
3 Publications  47 
 
  
3 Publications  48 
 
  
3 Publications  49 
 
  
3 Publications  50 
 
  
3 Publications  51 
 
  
3 Publications  52 
 
  
3 Publications  53 
 
  
3 Publications  54 
 
  
3 Publications  55 
 
  
3 Publications  56 
 
3 Publications  57 
 
Publication 3 
 
 
Comparative Assessment of female mouse of Graves’ or-
bitopathy under different environments, accompanied by 
proinflammatory cytokine and T-cell response to thyrotro-
pin hormone receptor antigen. 
 
Berchner-Pfannschmidt U, Moshgelgosha S, Diaz-Cano S, Edelmann B, Görtz G-E, 
Horstmann M, Noble A, Hansen W, Eckstein A, Banga J. P. 
 
Endocrinology. 2016, 157(4):1673-1682 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contribution 
Herein, I was involved in immunization procedure of the mice with TSHR A-subunit and 
ß-galactosidase encoding plasmids. After scarification of the mice I contributed to prep-
aration of orbital tissue and performed cell culture experiments. I was involved in dis-
cussing and analyzing data. 
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Publication 4 
 
 
Pathogenic phenotype of adipogenesis and hyaluronan in 
orbital fibroblasts from female Graves' orbitopathy 
mouse model 
 
Görtz G-E, Moshkelgosha S, Jesenek C, Horstmann M, Edelmann B, Banga JP,  
Eckstein A, Berchner-Pfannschmidt U 
 
Endocrinology. 2016 Oct; 157(10):3771-3778 
 
 
 
 
 
 
 
 
 
 
Contribution 
In this study, I established cell culture of mouse OF and investigated growth and pro-
liferation of the cells (Fig. 1). I was involved in detection of surface marker by flow 
cytometry and performed western-blot analysis of target antigens and proteins (Fig. 2, 
4). I designed the experimental conditions and conducted adipogenic and myogenic 
differentiation assays (Fig. 3) and hyaluronan ELISA (Fig. 4). I designed all experi-
ments, analyzed the obtained data and interpreted the results. I contributed to writing 
of abstract, introduction, methods, results and discussion of the publication. 
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4 Discussion 
The pathogenesis of Graves’ orbitopathy (GO) is very complex and molecular pro-
cesses are not fully understood. The physical and mental burdens of GO patients are 
high and the development of new treatments and therapies must be encouraged. It is 
known that orbital fibroblasts (OF) fulfill a central role in the pathophysiology of GO and 
activated OF enhance tissue remodeling and inflammatory processes in the orbit 
(Bahn, 2010). The causal roles of pathophysiological processes in GO need more in-
sight in OF activation as well as signal cascades and this may provide new therapeutic 
targets. In this thesis, the orbital cell populations were isolated, investigated and char-
acterized. Further the causal role of hypoxia and HIF-1 dependent pathways for tissue 
remodeling in GO was discovered. Furthermore, the implementation of a new GO 
mouse model and the isolation and characterization of mouse OF (mOF) complete this 
work. 
4.1 Characteristics of human orbital cell population - orbital 
fibroblasts and mesenchymal stem cells 
Since orbital fibroblasts (OF) cell cultivation derived from fat biopsies of GO patients 
has been established in 1987 (Bahn et al., 1987) various in vitro studies identified the 
OF as the key players in GO pathology. Previous studies indicated that OF may share 
some characteristics with mesenchymal stem cells (MSCs) like expression of CD90 
and potential to differentiate into adipocytes and myocytes (Koumas et al., 2002; Smith 
et al., 2002; Meyer zu Horste et al., 2011). Mesenchymal stem cells (MSC) are undif-
ferentiated fibroblastic like non hematopoietic progenitor cells which are able to differ-
entiate into mesenchymal (fat, bone, cartilage and muscle) and non-mesenchymal lin-
eages (neuron) (Le Blanc and Mougiakakos, 2012). This suggests that MSC are an 
important component in tissue remodeling as well as immune response (Uccelli et al., 
2008). Furthermore, MSC are characterized by regenerative and immunoregulatory 
properties, indicating MSC as an interesting cellular treatment tool for inflammation and 
autoimmunity. Little has been known so far about tissue-resident mesenchymal pro-
genitor cells in the retrobulbar connective/fat tissue of GO patients and about the inter-
relation of fibroblasts and MSC in this tissue.  
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Therefore, in our study we derived GO-MSC and GO-OF simultaneously from the or-
bital adipose tissue of GO patients. Our results show that GO-OF exhibit similar mor-
phological features, surface marker sets and differentiation potentials like GO-MSCs 
(Publication 1, Fig. 1-3). In addition, loss of CD31 and CD146 in early passages (Pub-
lication 1, Fig. 2 and Supplementary Fig. S1) was described as a characteristic of mes-
enchymal progenitor cells from orbital fat tissue (Chen et al., 2014). This suggesting 
that both GO-OF and GO-MSC have characteristics of fat derived stem cells. Interest-
ingly, we found that GO-MSC and GO-OF are able to differentiate in adiogenic, osteo-
genic, chondrogenic, myogenic and neurogenic lineages (Publication 1, Fig. 3). The 
ability of GO-OF to differentiate in adipocytes and myocytes (Valyasevi et al., 1999; Lin 
et al., 2013; Chen et al., 2014) has been known but we could also show their ability to 
differentiate along the osteogenic, chondrogenic, and neuronal lineages. However, 
GO-MSC showed a better differentiation potential than the GO-OF in relation to adipo-
genesis, osteogenesis and myogenesis. This suggests that OF from retrobulbar adi-
pose tissue from GO patients contain lesser mesenchymal stem cells and more mature 
differentiated cells. In contrasts, potential MSC isolated from ethmoid of the same GO 
patients (GO-EthC) showed any multilinage differentiation capacity and constitutively 
expressed α-SMA indicating that these cells are myofibroblasts with an absence of 
MSC populations. In addition, fibroblast isolated from eyelid skin during blepharoplastic 
have similar cell surface marker as orbital fat-derived stem cells but did not show the 
same differentiation characteristics (Lin et al., 2013). The cells did not differentiate to 
the adipogenic or osteogenic lineage and have a less powerful ability of chondrogenic 
differentiation (Martins et al., 2014). The multilineage differentiation potential of MSC 
populations of bone marrow cells from different species and the ability to differentiate 
in multilineages is well discovered. It has been also reported that MSC are hetero-
genous regarding of their multilineages differentiation potential. The MSC pool in bone 
marrow comprised subpopulations at various differentiation states (Baksh et al., 2004). 
Likewise orbital fibroblast population may contain also subpopulations and many dif-
ferentiation states. The function and heterogeneous character of the cell subpopula-
tions within the orbital fat tissue is not fully enlightened and need further investigations. 
Another aspect of heterogeneity within the orbital population is a different degree of 
CD90 (Thy-1) expression on the cell surface. It is known that the presence of CD90 
influences the differentiation ability (Koumas et al., 2002; Douglas et al., 2010; Smith, 
2010). CD90 positive subtypes have a higher capacity to differentiate into myocytes 
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and CD90 negative subtypes differentiate into adipocytes (Koumas et al., 2002; Kou-
mas et al., 2003). We found that GO-MSC and GO-OF were merely CD90 positive but 
OF from some GO patients (two out of nine patients) showed indeed a CD90 negative 
subpopulation (Publication 1, Fig. 2). As described earlier, GO-MSC demonstrated a 
higher adipogenic and myogenic differentiation potential than GO-OF (Publication 1, 
Fig. 3), but the CD90 expression in both populations was very similar (Publication 1, 
Fig. 2). This suggests that other factors than CD90 expression are also considered to 
impact differentiation capacity of orbital subpopulations. Adipogenic differentiation can 
also be induced by stress under pressure shown in a three-dimensional culture model 
as might occur in the diseases orbit (Li et al., 2014). Therefore, it is necessary to in-
vestigate the orbital cells in terms of adipogenic/myogenic differentiation capacity as 
well as proliferation and hyaluronan production (Publication 1, Fig. 1) under inflamma-
tory conditions which are present in the diseased orbit. The role of osteogenic, chon-
drogenic and neuronal differentiation pathways is completely unknown in context of 
GO pathology. In our study we investigated characteristics of MSC and OF derived 
from GO patients but studies with MSC and OF derived from healthy control persons 
are needed to fully understand the role of stems cells for remodeling and expansion of 
the retrobulbar fat tissue. 
Additional to the self-renewal potential and differentiation capacity MSC also have an 
immunoregulatory ability (Baksh et al., 2004). This immunoregulatory abilities include 
immunosuppressive and proinflammatory properties and can act as switchers of in-
flammation. MSC can influence the adaptive and the innate immune cells and are an 
underestimated player in local immune regulation (Bernardo and Fibbe, 2013). In con-
trast, GO-OF are important as regulators of immune cell recruitment and activation 
(Bahn et al., 1998; Cao et al., 1998; Hwang et al., 2009). Because GO-MSC are in-
volved in local immune regulation we investigated the potential role of GO-MSC in or-
bital immunology. We tested key features of immunologic cell-cell interactions such as 
suppression of T-cell proliferation and secretion of inflammatory cytokines and com-
pared the results with results of GO-OF. The results demonstrated that GO-MSC were 
more effective in suppression of T-cell proliferation (Publication 1, Fig. 4) and a higher 
secretion of IL-6 cytokine (Publication 1, Fig. 5). The constitutively secreted IL-6 by 
MSC assists in polarization of monocytes into pro-inflammatory M2 macrophages. In 
absence of IL-6 MSC help monocytes by polarization into proinflammatory M1 macro-
phages and this stimulates the T-cell activation (Bernardo and Fibbe, 2013). Our study 
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gives first evidence that GO-MSC represent an anti-inflammatory cell type with the re-
sult of inflammation inhibition. Interestingly, it was shown already during cornea injury 
orbital fat-derived stem cells could dampen inflammation (Lin et al., 2013). Studies of 
the immunological potential of GO-MSC and control-MSC could give a further insight 
in orbital pathology and can help to find promising therapeutic approaches for GO. 
With our study we could show the first time that mesenchymal progenitor cells (GO-
MSC) are present in the orbital fat tissue of GO patients. However, we also showed 
the GO-OF have the same biological characteristics like GO-MSC but the differentia-
tion potential, T-cell suppression and cytokine release reported some functional differ-
ences. Important is to investigate the function and population properties of orbital MSC 
from healthy control persons to better understand the pathological processes of GO. 
A further important cell type involved in GO pathogenesis are fibrocytes which are 
bone-marrow derived MSC (Smith, 2015). Fibrocytes play a role in wound healing, tis-
sue remodeling and immune function. They are extremely rare present in blood circu-
lation of healthy persons but their presence is dramatically increased in pathological 
states like tissue injury (Douglas et al., 2010). Likewise, Smith and colleagues found 
increased fibrocytes levels in the peripheral blood and in the orbital tissue of GO pa-
tients (Smith, 2010; Douglas et al., 2010). Fibrocytes just like OF expressed the target 
antigen TSHR and IGF-1R, showed CD90 heterogeneity and were able to differentiate 
in adipocytes and myocytes. The role of fibrocytes for pathogenesis of GO and their 
potential relation to OF or MSC is currently unknown. 
Hypoxia is a well-known factor driving MSC development, maturation and differentia-
tion (Ejtehadifar et al., 2015). The natural microenvironment in bone-marrow are drawn 
by a low oxygen content and the cells are able to deal with the conditions or adapt 
themselves. Through the inflammation and tissue expansion in the orbit it is also pos-
sible that some patients develop hypoxic conditions in the orbit where present GO-
MSC and GO-OF have to adapt. Tissue hypoxia triggers the activation of many cellular 
pathways trough the stimulation of many genes and proteins involved in angiogenesis 
and adipogenesis. This suggests that hypoxic signaling in orbital fibroblasts popula-
tions could play an important role during tissue expansion and differentiation pro-
cesses. 
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4.2 Orbital fibroblasts under influence of hypoxia - role of hypoxia 
for tissue remodeling 
Hypoxia plays a role in tissue augmentation and differentiation processes of many tis-
sue types, e.g. in adipogenesis of MSC (Ejtehadifar et al., 2015). Increasing tissue 
expansion and inflammation processes as well as swelling of the tissue in the limited 
space of the bony orbit, leads to local chronic hypoxic conditions. Key regulator of hy-
poxia is the transcription complex hypoxia-inducible factor 1 (HIF-1), which regulations 
the expression of genes which are involved in the clinical manifestation in the GO path-
ogenesis. The pathogenesis of GO is determined by many factors. One of these factors 
is the consumption of cigarette smoke. Cigarette smoke is a strong risk factor for the 
course and severity of the GO. The establishment of GO and smoking is associated 
with a 1-3 fold increase in overall incidence of symptomatic and an 2-6 fold as well as 
3-1 fold increase in the incidence of proptosis and diplopia (Pfeilschifter and Ziegler, 
1996; Vestergaard, 2002). 
Therefore, we investigated how hypoxia-dependent and hypoxia-independent HIF-1 
signaling may contribute to tissue remodeling in GO. Orbital fibroblasts are considered 
as the central cell type in inflammation and tissue remodeling in GO. We could show 
that orbital fibroblast derived from GO patients responded more sensitively toward hy-
poxia than orbital fibroblasts from control persons. This was shown by increased in-
duction of HIF-1α (Publication 2, Fig. 1) as well as enhanced HIF-1 transcriptional ac-
tion (Publication 2, Fig. 2, 3, 5) which leads to enhanced angiogenesis (Publication 2, 
Fig. 3, 4) and adipogenesis (Publication 2, Fig. 5). Furthermore, we could show that 
cigarette smoke extract elevates hypoxic-induced HIF-1α accumulation in OF from GO 
smoker (Publication 2, Fig. 6). 
Angiogenesis, in pathological sense is a critical mediator of neovascularization in dis-
orders like eye diseases, cancer formation, chronic inflammatory disorders such as 
rheumatoid arthritis (RA), proriasis and periodontitis (Penn et al., 2008; Sene et al., 
2015). We found that in GO derived fat/connective tissue CD31 positive vessels were 
dramatically increased compared to control fat tissue (Publication 2, Fig. 4 and Sup-
plementary Fig. 1). Since CD31 is a marker of newly developing vessels (Wang et al., 
2008) it appeared that during adipose tissue expansion in the orbit neovascularization 
occurred most likely to overcome low oxygen concentration in the tissue. This is re-
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flected by increased HIF-1α in cells of the fat/connective tissue of GO patients (Publi-
cation 2, Fig. 4). The results indicate that hypoxia was present in the tissue of GO 
patients. HIF-1 induced by hypoxic conditions can stimulate production of genes e.g. 
VEGF and PDFG driving the angiogenic processes. The tissue enlargement especially 
by adipogenesis, which is one of the most present processes in the pathology of GO, 
require a continuous remodeling of the vasculature to survive. 
The increased adipose tissue in GO patients can be caused by de novo adipogenesis 
of OF also called preadipocytes (Kumar et al., 2005) or by adipose tissue derived mes-
enchymal stromal/stem cells (Publication 1). The adipogenic differentiation stimulated 
by activating anti-TSHR antibodies, TSH or various growth factors and cytokines like 
IL-1β and IL-6 is known (Cawood et al., 2006; Kumar et al., 2010; Kumar et al., 2011; 
Virakul et al., 2015). In the present study we could show that hypoxia induced adipo-
genic differentiation in an HIF-1 dependent manner in OF derived from GO patients 
whereas Ctrl-OF were mainly unaffected (Publication 2, Fig. 5). The adiponectin re-
lease of GO-OF during adipogenic differentiation (Publication 2, Fig. 5) was increased 
in agreement with the enhanced adiponectin gene expression found in GO orbital fat 
of previous studies (Kumar et al., 2005; Marique et al., 2015). These findings indicate 
that hypoxia is an important factor for the induction and stimulation of adipogenesis of 
the orbital tissue independently from other stimulating factors. The contribution of or-
bital MSC population to adipogenesis in GO remains to be investigated. However, in 
other studies adipogenic differentiation of MSC was depended on the severity and du-
ration of hypoxic conditions. Whereas short duration leads to adipogenic differentiation 
long time exposure towards hypoxia inhibited adipogenesis (Buravkova et al., 2014). 
The adipose tissue and OF from GO patients expressed TSHR to higher levels than 
control persons (Bahn et al., 1998; Bahn, 2010). Our result show that additional to 
hypoxia the stimulation of the TSHR using TSH leads to augmented adipogenesis of 
GO-OF and also to a low induction of adipogenic differentiation of Ctrl-OF (Publication 
2, Fig. 5). The combination of hypoxia and TSHR stimulation increased adipogenesis 
to highest levels. This result is especially important for the clinical treatment of these 
patients. Poor control of thyroid function – long period of hypothyroidism with increased 
levels of TSH will foster adipogenesis and set up a circulus vitiosus in the volume lim-
ited bony orbit. In this context, hypoxia turned out to be an important factor which de-
termines the extent of orbital fat expansion. The occurrence or degree of hypoxia de-
pending of the configuration of the bony orbit in the orbital tissue of individual patients 
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could be an explanation why some patients develop fat tissue to high levels whereas 
other patients only show low or moderate fat expansion. Another main feature of GO 
pathogenesis is the overproduction of hyaluronan in the orbit. OF are known to produce 
hyaluronan in response to TSHR and IGF-1R stimulation (Smith et al., 1991; Smith et 
al., 1995). Moreover orbital adipogenesis is associated with increased hyaluronan pro-
duction (Zhang et al., 2012). Thus hypoxia by stimulating adipogenesis can also con-
tribute to hyaluronan overproduction in the orbit. In this respect it was shown earlier 
that hypoxia enhanced glycosaminoglycan production in OF derived from EOM of GO 
patients (Metcalfe and Weetman, 1994). These findings imply that hypoxia dependent 
pathways are involved in enhanced adipogenesis as well as overproduction of extra-
cellular matrix both of which contributes to the excessive tissue expansion within the 
limited bony orbit of GO patients. 
4.2.1 Hypoxia-inducible factor 1 dependent pathways in orbital 
fibroblasts 
Cells respond to hypoxia by adapting gene expression trough the activation of hypoxia-
inducible factor 1 (HIF-1). HIF-1 has been recognized as the master regulator of oxy-
gen homeostasis both in physiology and pathophysiology (Semenza, 1998). HIF-1 co-
ordinates the hypoxia-inducible expression of angiogenic factors such as vascular en-
dothelial growth factor (VEGF) and thus finally coordinates tissue vascularization. Hy-
poxia induced the expression of glucose transporters (GLUT), and many HIF-1 de-
pendent genes promote excessive proliferation, matrix formation, differentiation and 
adipogenesis (e.g. adiponectin) (Publication 2, Fig. 5). As described above, OF repre-
sent the key cell type in tissue activity and remodeling processes in the dysregulated 
orbital tissue of GO patients. These cells react more sensitively towards hypoxia and 
showed an increased HIF-1α accumulation than Ctrl-OF (Publication 2, Fig. 1). The 
increased HIF-1α induction was positively correlated with the clinical activity score of 
GO patients, indicating a relationship between inflammatory/immunological degree 
and hypoxic reaction (Publication 2, Fig. 1). The OF derived from GO patients showed 
also enhanced basal expression of HIF-1α mRNA, independently from oxygen concen-
tration applied indicating that the other factor than hypoxia promote HIF-1 expression 
in OF of GO patients. (Publication 2, Fig. 2). Inflammation and immunity can activate 
several signaling pathways which are involved in stimulation of HIF-1α synthesis 
(Frede et al., 2006; Rius et al., 2008). It is also known that NF-κB and MAPK pathways, 
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inducible by inflammatory mediators like IL-1β or CD40 ligand, impacts on HIF-1α up-
regulation. On the other site HIF-1 can also activate NF-κB (Jung et al., 2003; Frede 
et al., 2007; Choi et al., 2013; Wang et al., 2015). Thus NF-κB and HIF-1 can occur in 
a cross-talk and hypoxia can activate both transcription factors resulting in an HIF-
1/NF-κB loop during inflammatory hypoxia (Cummins et al., 2006; van Uden et al., 
2008). The exact role of NF-κB/HIF-1 pathway and the cross-talk between both tran-
scription factors needs further investigation in context of GO pathogenesis. 
VEGF is well known as a target gene of HIF-1 and is the main growth factor of angio-
genesis. As described above our results show increased new vessel development in 
fat tissue and enhanced HIF-1α accumulation in fat tissue and OF from GO patients 
(Publication 2, Fig. 1, 4). Additional, we found an induction in VEGF production by OF 
as a direct consequence of HIF-1 action (Publication 2, Fig. 3). This increased VEGF 
secretion could also be responsible for the increased vascularization, which can pro-
mote tissue remodeling (Thesis Fig. 10). In addition, the elevated adipogenesis of OF 
derived from GO patients in response to hypoxia was inhibited by HIF-1 activation in-
hibitor BAY 87-2243 (Publication 2, Fig. 5) suggesting that HIF-1 action also is involved 
in adipogenic differentiation. 
Smoking is one of the strongest risk factor of GO and it has been shown that cigarette 
smoke extract (CSE) increased adipogenic differentiation and hyaluronan acid produc-
tion in GO-OF (Cawood et al., 2007; Yoon et al., 2013). To investigate, whether HIF-
1α is affected by smoking we treated OF from GO smoker and non-smoker with CSE 
under hypoxic conditions. We found that HIF-1α was elevated in response to CSE in 
OF derived from GO smoker whereas HIF-1α in OF derived from non-smoker remains 
unaffected (Publication 2, Fig. 6). Smoking GO patients show stronger eye symptoms 
than non-smoking GO patients. The average incidence of smokers is four times higher 
than of non-smokers (Vestergaard, 2002) and the cessation of cigarette consumptions 
alleviated symptoms (Pfeilschifter and Ziegler, 1996). One reason could be the combi-
nation of hypoxia and compounds of the cigarette smoke, which lead to an over-acti-
vation of HIF-1 pathways and thus development of sever proptosis and/or myopathy in 
smokers. 
In conclusion hypoxia and HIF-1 dependent pathways can play a causal role in the 
tissue remodeling of GO by induction of important factors like VEGF and adiponectin, 
which stimulate the neovascularization and adipogenic differentiation (Thesis Fig. 10). 
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Both processes are involved in the tissue expansion in the orbit. Hypoxia is also known 
to favor inflammatory processes and plays a role by recruitment of inflammatory cells 
and immune cells in tissues (Haddad and Harb, 2005; Kiers et al., 2016). The role of 
hypoxia for inflammation or immunity of the orbital tissue in GO is subject of further 
studies. 
Figure 10. Involvement of HIF-1 dependent pathways in the pathological processes of 
GO. Under hypoxic conditions OF produce HIF-1α. Increased HIF-1α levels lead to stimulation 
of adipogenic differentiation of OF and increase hyaluronan production both of which are 
associated with volume entlargment of the orbital tissue. Additionally, stimulation of the TSHR 
by TSH or autoantibodies leads to an augmented adipogenesis. Furthermore, increased HIF-
1a levels lead to elevated VEGF secretion of OF promoting neovascularisation during tissue 
enlagement. Thus HIF-1 dependent pathways contribute to expansion of orbital tissue. The 
role of HIF-1 in orbital inflammation and autoimmunity processes remains to be investigated. 
4.2.2 Clinical relevance of hypoxia in Graves’ orbitopathy 
From today’s point of view the main treatment for moderate-to-severe and sight-threat-
ening GO is the medication of immunosuppressive corticosteroids and orbital decom-
pression surgery. Bony orbital decompression is predominantly applied to GO patients 
with sight-threatening symptoms or when the anti-inflammatory treatment failed 
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(Bartalena et al., 2008; Salvi and Campi, 2015). Our results give first evidence that the 
control of HIF-1 pathway is important to control tissue expansion in GO. From clinical 
observations it is known that poor control of thyroid function, promotes a more severe 
course of GO (Prummel et al., 1990; Tallstedt et al., 1994). The observed cumulative 
effect of hypoxia and TSH on adipogenesis could explain why the thyroid gland treat-
ment should be carefully planned especially in GO patients with advanced stages to 
prevent long periods of elevated TSH levels due to hypothyroidism. The development 
of treatments which prevent uncontrolled stimulation of the TSHR in response to TSAb 
binding is equally or even more important at this background. The recently established 
GO mouse model (Publication 3) will allow us to study the role of HIF-1 pathways and 
new therapeutic targets in vivo. 
4.3 Establishment of GO mouse model and derived orbital 
fibroblasts 
Graves’ disease (GD) is the most common autoimmune disorder, affecting approxi-
mately 2-5% of the Caucasian population. In which, Graves’ orbitopathy represents 
with 25-50% of Graves’ patients the most frequent extrathyroidal manifestation 
(Wiersinga and Bartalena, 2002; McLachlan et al., 2005). There are no reports that 
animals spontaneously develop a GD. However, since Graves’ disease is known to be 
due to an autoimmune mechanism, various approaches have been developed for the 
immunological induction of disease in animals. These approaches included injection of 
TSHR transfected fibroblasts or injection of plasmids or adenovirus encoding for the 
extracellular subunit of the human TSHR (Banga et al., 2015; Moshkelgosha et al., 
2015; Banga et al., 2016). Most of these models were successful in induction of GD. 
However, some of these models were only for short time period or were self-limiting 
and showed almost no eye symptomatic or eye symptoms where not reproducible. The 
first preclinical GD mouse model including full blown GO pathology was developed by 
Banga and co-worker in 2013 (Moshkelgosha et al., 2013). We initiated a collaboration 
and conducted a comparative study in which we established the GO mouse model in 
our laboratory. During the course of the GO mouse study we demonstrated the ex vivo 
cultivation and characterization of orbital fibroblast from GO mice and controls. We 
investigated the pathologic cell type by discovering the adipogenic differentiation abil-
ity, hyaluronan production and expression of receptors involved in GO pathology. 
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4.3.1 Establishment of GO mouse model 
Animal housing and environmental factors can critically influence the development, 
disease incidence and severity of autoimmune conditions of animal models. To evalu-
ate the outcome of GO in the GD mouse model in our laboratory compared to the 
outcome of the model in Banga’s laboratory we conducted a parallel study in which we 
used the same mouse strain (BALB/cOlaHs) and performed the immunization protocol 
of the mice as described before (Moshkelgosha et al., 2013). The outcome of the GO 
mouse model was similar in both laboratories. All mice develop TSHR autoantibodies 
(TRAbs) to high levels with different levels of stimulating (TSAbs) and blocking 
(TSBAbs) antibodies (Publication 3, Fig. 1). Additionally, some mice developed anti-
IGF-1R antibodies (Publication 3, Fig. 1). The mice developed hyperthyroidism but re-
mained mainly euthyroid in our laboratory (Publication 3, Fig. 1) which was confirmed 
by histology of the thyroids (Publication 3, Supplementary Fig. 2). Hyperthyroidism or 
euthyroidism is most likely the result of the action of the respective mixture of stimulat-
ing and blocking antibodies either activating or blocking the TSHR of the thyroids. How-
ever, the outcome of GO pathology was very similar in the mice of both of the labora-
tories. Some of the mice showed chemosis (sterile inflammation) of the eye lids but 
proptosis or diplopia was not evident. However, examination of the retroorbital tissue 
revealed expansion of the adipose tissue and atrophic EOM (Publication 3, Fig. 2). 
Since the mice behaved like GO patients by developing either more fat expansion or 
myopathy we normalized and combined both features by Z scoring to obtain a total eye 
disease score (Publication 3, Figure 2). The total eye disease score revealed that the 
overall outcome of GO was very similar in the mice of both laboratories. To confirm a 
TSHR antigen specific T cell response in the immune mice, we investigated prolifera-
tion and cytokine release of splenic T cells in response to recombinant TSHR antigen. 
We found a significant splenic T-cells response under recombinant TSHR antigen stim-
ulation and high levels of cytokine (IFN-γ, IL-10, IL-6 and TNF-α) secretion (Publication 
3, Fig. 3). However, we could not show any correlation between cytokine secretion and 
orbital pathology indicating that the orbital pathology is more complex than merely the 
secretory cytokine pattern. 
In conclusion, we could show that the preclinical mouse model induced by hTSHR-A-
subunit immunization is a well-functioning animal model and reproducible in different 
environment exposures. Orbital pathology was reproducible and present in 80% of 
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mice undergoing GO. To investigate the role of orbital fibroblast for pathology of ex-
perimental GO in the mice we established ex vivo cultivation of OF from mice orbits 
undergoing GO in our laboratory. 
4.3.2 Characterization of orbital fibroblasts derived from GO mouse 
model and comparison to human orbital fibroblast 
Herein, we demonstrated ex vivo cultivation and characterization of OF derived from 
GO mice and control mice. Additionally, we show mouse OF (mOF) inherent ability for 
adipocyte differentiation and hyaluronan production when activated by a variety of lig-
ands, including TSH and IGF-1. The aim was to identify the pathological cell type in 
orbital tissue from mice undergoing experimental GO and to investigate whether there 
showed similar properties to those derived from human GO patients.  
For establishment of mOF cell culture we used the orbital tissue from one eye of the 
respective immune mice from the recently described study (see 4.3.1). In in vitro stud-
ies of OF from GO patients the cells were derived either from fat/connective tissue or 
EOM (Bahn et al., 1987; Metcalfe and Weetman, 1994). Therefore we subjected 
mouse orbital tissue consisting of mainly EOM and partly connective/fat tissue to cell 
culture (Publication 4, Fig. 1). For examination of tissue components we used histolog-
ical analysis of the other eye of the respective mouse (Publication 4, Fig. 1). We could 
show that fibroblast like cells migrated out from the orbital tissue and adhered to a 
confluent monolayer (Publication 4, Fig. 1). We found no morphological and growth-
related differences between cells from GO mice and control mice (Publication 4, Fig. 
1). For characterization of the obtained cells we analyzed several surface marker, re-
ceptors and differentiation ability (Publication 4, Fig. 2, 3).  
The immune phenotype of mOF derived from GO and control mice were highly similar 
(Publication 4, Fig. 2). They were positive for MSC marker and negative for leukocyte 
marker indicating their mesenchymal cell immune phenotype akin both to mouse bone 
marrow stem cells or embryonic fibroblasts as well as human OF (Meyer zu Horste et 
al., 2011; Saeed et al., 2012; Kozdon et al., 2015). In contrast mOF were negative for 
the MSC marker CD73 showing that the cells derived from mouse orbits are similar but 
not identical to cells derived from GO orbital fat tissue (Publication 1; (Meyer zu Horste 
et al., 2011). CD73 is a catabolic enzyme leading to the generation of immunosuppres-
sive, pro-angiogenic and negatively regulating Th1 adenosine (Chrobak et al., 2015; 
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Antonioli et al., 2016). An inhibition or deficiency favored autoimmune conditions like 
arthritis in mice (Chrobak et al., 2015). The role of CD73 in GO still requires extensive 
investigations. Further, mOF expressed mainly high levels of CD90.2, the BALB/c spe-
cific Thy 1 allele (Publication 4, Fig. 2). Interestingly, mOF derived from GO mice ex-
pressed CD90.2 more frequently to low levels compared to Ctrl mOF (Publication 4, 
Fig. 2). But unlike to findings in human OF derived from GO patients, the mOF derived 
from GO mice did not present distinct CD90 positive and CD90 negative populations 
(Smith et al., 1995); Publication 1). In humans the portion of these subpopulations are 
dependent on the derived orbital region. CD90 negative cells were more abundant in 
orbital adipose tissue and CD90 positive cells were predominantly found in EOM 
(Smith et al., 2002). In our study the main body of investigated orbital tissue was EOM 
suggesting that the high CD90.2 expression of mOF reflects their EOM origin. To in-
vestigate myogenic differentiation we analyzed expression of α-smooth muscle actin 
(α-SMA). We could show that mOF constitutively expressed high levels of α-SMA 
which was not further elevated in response to TGF-β stimulation (Publication 4, Fig. 3). 
The high expression of α-smooth muscle actin characterize the mOF as myofibroblastic 
cell type and could be a further indication for the EOM origin of the cells (Koumas et 
al., 2003). In contrast, human OF were frequently isolated from orbital connective/fat 
tissue of GO patients (for comparison see Thesis Table 1) and only a few studies using 
OF derived from EOM of GO patients exist (Metcalfe and Weetman, 1994). Further-
more, these studies did not phenotypically characterize OF derived from EOM to clarify 
similarities and differences compared to OF derived from fat tissue. Whereas biopsies 
from fat tissues are obtained during decompression surgery of GO patients in active 
stage, biopsies from EOM of GO patients can be obtained during surgery of diplopia. 
However, surgery of diplopia takes place after treatment of inflammation using steroids 
driving the eye disease in an inactive stage. Nevertheless we obtained OF from an 
EOM biopsy of a diplopia patient (without GO) and could show constitutively α-SMA 
expression of the cells as observed for mOF (Thesis Supplementary Fig. 1). This initial 
result indicates that indeed myofibroblast-like cells can be also derived from human 
EOM tissue. Further studies are needed to characterize different fibroblast populations 
in fat or EOM and their contribution to GO subtype with either more fat expansion or 
myopathy. 
The main target genes of GO pathology are the TSHR and IGF-1R, both are highly 
expressed in GO orbital tissue and OF (Starkey et al., 2003; Wakelkamp et al., 2003; 
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Smith, 2009). In previously studies, it could be shown that TSHR is highly expressed 
in retro-orbital tissue of different mice strains (Johnson et al., 2013; Wiesweg et al., 
2013). In our study we found also TSHR and IGF1R expression in mOF derived from 
GO and control mice (Publication 4, Fig. 2). Additionally, we could show that mOF from 
GO mice expressed higher levels of TSHR and IGF-1R compared to control mOF (Pub-
lication 4, Fig. 2). Further, we investigated the expression of CD40 and found high 
expression in mOF derived from GO mice (Publication 4, Fig. 2). High expression of 
CD40 is also known in human OF and the interaction between OF and T cells via 
CD40-CD154 and various cytokines increase the proliferation rate, adipogenic differ-
entiation and hyaluronan production of OF (Heufelder and Bahn, 1994; Cao et al., 
1998; Feldon et al., 2005; Feldon et al., 2006). The ligation of CD40-154 with T-cells 
could be another pathway which plays a role in the pathogenic processes of GO in 
mice and needs further investigations. 
The investigation of adipogenic differentiation potential and hyaluronan production re-
vealed a significant difference between GO and control derived mOF (Publication 4, 
Fig. 3, 4). The GO mice derived mOF showed stronger adipogenic differentiation po-
tential than control mOF which remained less responsive (Publication 4, Fig. 3). This 
suggest that mOF derived from GO mice contained more substantially preadipocyte 
like cells which are capable to differentiate in mature adipocytes just like human OF or 
MSC populations from GO patients (Publication 1; (Kumar et al., 2004). It is known that 
CD90 negative human OF have a high capacity to differentiate into adipocytes (Smith 
et al., 2002). Therefore, it is tempting to speculate that the CD90.2 low expressing mOF 
were responsible for the higher adipogenic differentiation ability of mOF derived from 
GO mice. Increased hyaluronan production can be caused by activated OF/preadipo-
cytes through stimulation of TSHR or IGF-1R (Smith and Hoa, 2004; Zhang et al., 2009; 
Zhang et al., 2012; Krieger et al., 2015). Treatment of human OF with TSH or IGF-1 
stimulated hyaluronan secretion and simultaneous treatment with TSH and IGF-1 
acted synergistically (Krieger et al., 2015). In agreement with these findings, the mOF 
derived from GO mice secreted elevated levels of hyaluronan compared to control 
mOF in response to TSH and/or IGF-1 as well as in response to stimulating anti-TSHR 
antibody M22 (Publication 4, Fig. 4). The hyaluronan production is controled by three 
hyaluronan synthases (HAS1-3), in which HAS 2 represents the main contributor of 
hyaluronan overproduction in the human orbit (Publication 4, Fig. 4). Altogether, the 
overexpression of TSHR, IGF1R and HAS2 in connection with TSH and/or IGF-1 or 
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M22 stimulation contributed to an increased hyaluronan secretion of OF derived from 
GO mice just like in GO patients. 
Earlier we found a role of Hypoxia-inducible factor 1α (HIF-1α) for tissue remodeling in 
GO patients (Publication 2). OF from GO patients expressed increased HIF-1α accu-
mulation compared to OF derived from control patients (Publication 2, Fig. 1). Likewise 
we found that mOF derived from GO mice showed significantly increased HIF-1α levels 
under hypoxic conditions compared to mOF from control mice (Thesis Supplementary 
Fig. 2). This result represents the findings in human OF and studies are underway to 
confirm the role of HIF-1 action for tissue remodeling in GO mice. Moreover the role of 
HIF-1 can be proven in mice model by using HIF-1 -/- (knock out) mice. It is also pos-
sible to study the course of hypoxic effects and smoking in individual stages of the 
disease in the GO mouse model. 
In summary, our data give first evidences that mouse OF substantially affected in re-
sponse to hTSHR A-subunit immunization and recapitulate the main features of OF 
derived from GO patients (Thesis Table 1). Therefore, the mouse OF can be consid-
ered as pathogenic target cell type responsible for tissue expansion in the orbit of GO 
mice. One important question raised is why and when OF were activated and/or 
changed into a pathologic phenotype in response to autoimmunity during the course 
of the disease. In immunized mice OF will be derived from all stages of GO and 
changes will be investigated in response to various kinds of treatments. This will lead 
to a better insight of disease pathogenesis and is fundamental to develop potential 
novel therapeutic targets. 
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Table 1. Comparison of fibroblastic cells involved in GO. Comparison of orbital fibro-
blastic cells derived from GO patients and GO mice. The table shows some properties of 
orbital cells from GO patients and GO mice. Results obtained from Publication 1, 2, 4, and 
from *Thesis Supplementary Fig. 2, 3. **Already fully myogenic differentiated; nd, not deter-
mined; MSC, mesenchymal stem cells; EOM, extraocular muscle. 
 GO patients GO mice 
Tissue origin Connective/fat tissue Mainly EOM, partly fat 
Cell type 
Fibroblasts/Preadipo-
cytes/MSC 
Myofibroblasts 
MSC marker 
CD29+, CD44+, CD105+, 
CD73+, CD90-/+ 
CD29+, CD44+, CD105+, 
CD73-, CD90 low/high 
Leucocyte marker CD45-, CD11b- CD45-, CD11b- 
Target antigen TSHR+, IGF-1R+ TSHR+, IGF-1R+ 
T-cell interaction CD40+ CD40+ 
Adipogenesis + + 
Myogenesis + -** 
Osteogenesis + +* 
Chondrogenesis + nd 
Neurogenesis + nd 
Hyaluronan production + + 
Hypoxia HIF-1α induction HIF-1α induction* 
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6 Appendix 
6.1 Supplementary Figures 
 
Supplementary Figure 1. Myocyte differentiation of human OF derived from EOM. Human 
OF were derived from EOM biopsy of a diplopia patient (no GO). Cells of passage 1 were 
incubated with or without 500ng/ml TGF-ß for 48h to induce myogenic differentiation and im-
munostained for α-smooth muscle actin (α-SMA) (green). Cell nuclei were counterstained with 
DAPI (blue). Representative images are shown, x200, bar represents 100µm. Human OF de-
rived from EOM expressed basically α-SMA indicating constitutive myogenic differentiation. 
 
Supplementary Figure 2. HIF-1α accumulation in mouse OF. Mouse OF were subjected to 
normoxic (NOX) or hypoxic (HOX) conditions for 24 h. Whole cell lysates were subjected to 
Western-blot analysis for detection HIF-1α and β-actin as a loading control. Western-Blot sig-
nals of 10 GO-mOF and 6 Ctrl-mOF were quantified by densitometry of immunoblots. The HIF-
1α signal was normalized to the β-actin signal and expressed as relative HIF-1α protein. 
*P≤0.05, **P<0.01. Mouse OF derived from GO mice (GO) express more HIF-1α under hypoxia 
(HOX) than control mOF (Ctrl). No differences in HIF-1α expression were found under-
normoxia. 
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Supplementary Figure 3. Osteogenic differentiation of mouse OF. Mouse OF (passage 2-
4) from control (n= 8) and GO mice (n= 10) were subjected to differentiation assay. To induce 
ostegenic differentiation cells were cultivated with (GO osteo) or without (GO control) osteo-
genic differentiation medium for 21 days and stained with Alzian red as described earlier (Pub-
lication1). Representative images are shown x200, bar represent 100 µm. Mice OF derived 
from GO mice were substantially capable to osteocyte differentiation. 
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6.2 Abbreviations 
%   percent   
AdiQ   adiponectin   
Akt   protein kinase B   
bHLH   basic-helix-loop helix   
cAMP   cyclic adenosine monophosphate   
CAS   clinical activity score   
CBP   CREB binding protein   
CD   cluster of differentiation   
COLAGN  collagen   
CREB   cAMP response element-binding protein   
CSE   cigarette smoke extract   
C-TAD  C-terminal transactivation domain   
CTLA-4  cytotoxic T-lymphocyte-associated Protein 4   
Ctrl   control   
EOM   extraocular muscles   
EPO   erythropoietin   
ERK   extracellular signal-regulated kinases   
Fig.   Figure   
GAGs   glycosaminglycans   
GAPDH  glyceraldehyde 3-phoshatedehydrogenase   
GD   Graves’ disease   
GLUT   glucose transporter   
GO   Graves’ orbitopathy   
HAS   hyaluronansynthase   
HIF   hypoxia-inducible-factor   
HLA   human leucocyte antigen   
HRE   hypoxia response element    
hTSHR  human thyrotropin stimulating hormone receptor   
ICAM   intracellular adhesions molecule   
IGF-1R  insulin growth factor 1 receptor   
IL   interleukin   
LRRs   leucine rich repeats   
mOF   mouse orbital fibroblast   
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MSC   mesenchymal stem cell   
NF-κB   nuclear factor-kappa B   
N-TAD  N-terminal transactivation domain   
ODDD  oxygen-dependent degradation domain   
OF   orbital fibroblast   
PAS   period/ARNT/single minded domain   
PHD   prolyl hydroxylases   
PI3   phosphatidyl inositol 3   
PKA   protein kinase A   
PPAR   peroxisome proliferator-activated receptor   
PTPN22  protein tyrosine phosphatase, non-receptor type 22   
pVHL   von Hippel-Lindau tumor suppressor protein   
Raf   rapidly accelerated fibrosarcoma   
RCT   randomized controlled trial  
rhTSHR-E  recombinant hTSHR extracellular region protein   
ROS   reactive oxygen species   
siRNA   small interfering RNA   
SPF   specific pathogen free   
TBII   TSH-binding inhibitory immunoglobulin     
TGF-ß  transforming growth factor-ß   
TRAbs  thyrotropin-receptor autoantibodies   
TSAbs  TSH-stimulating antibodies   
TSBAbs  TSH-stimulating blocking antibodies   
TSH   thyrotropin stimulating hormone   
TSHR   thyrotropin stimulating hormone receptor   
VEGF   vascular endothelial growth factor   
α-SMA  α-smooth muscle actin    
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